Archive for April, 2012
Generic Challenge to Pfizer’s EpiPen by Teva and Antares (AIS, $2.70)
EpiPen is a self-administered injection of epinephrine used to avert anaphylactic shock following a severe allergic reaction, as with a bee sting. It is manufactured by Pfizer (PFE) and distributed by Mylan Laboratories (MYL). EpiPen is on track to exceed $300 million of US sales in 2012. Teva (TEVA) is first to file and is […]
Equity Offering Provides Discovery Laboratories Much Needed Financial Strength (DSCO, $2.81)
Report Summary With a number of cash infusions from a public offering, an ATM drawdown and warrant exercises, Discovery Laboratories (DSCO) has built a strong cash position. There remain a number of possible scenarios for how much more cash will come into the company depending on the exercise of the Green Shoe associated with the […]
Surfaxin Should Be Approved on its March 6th PDUFA Date (DSCO, $2.82)
Investment Thesis and Valuation The transformation of a biotechnology company from development stage to commercial can be the catalyst for a sustained increase in stock price. Discovery Laboratories (DSCO) received regulatory approval for its first product, Afectair, on February 2, 2012 and I believe that there is a strong possibility for approval of a second […]
Cadence: Product Recall Doesn’t Alter Sales Projections (CADX, $4.19)
I was somewhat alarmed to see a press release entitled “Cadence Pharmaceuticals Announces Voluntary Recall of One Lot of OFIRMEV® (Acetaminophen) Injection”. Cadence (CADX) is one of the stocks that I am recommending and my experience is that quality control issues can be very messy and disruptive. I wanted to follow-up with management to try […]